Biomaterial-based particulate drug carriers

Handbook of Harnessing Biomaterials in Nanomedicine

Volumn , Issue , 2012, Pages 1-20

  Margalit, Rimona ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84881735798     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.4032/9789814364270     Document Type: Chapter

References (65)

1. Torchilin, V.P. (2006) Multifunctional nanocarriers, Adv. Drug Deliv. Rev., 58, pp. 1532-1555.
2. Peer, D. et al. (2007) Nanocarriers: emerging platforms for cancer therapy, Nature Nanotechnol., 2, pp. 751-760.
3. Puri, A. et al. (2009) Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic, Crit. Rev. Ther. Drug. Carrier Syst., 26, pp. 523-580.
4. Kurmi, B.D. et al. (2010) Micro- and nanocarrier-mediated lung targeting (2010), Expert Opin. Drug Deliv. 7, pp. 781-794.
5. Muzykantov V.R. (2010) Drug delivery by red blood cells: vascular carriers designed by mother nature, Expert Opin. Drug Deliv., 7, pp. 403-427.
6. Senter, P.D. (2009) Potent antibody drug conjugates for cancer therapy, Curr. Opin. Chem. Biol., 13, pp. 235-244.
7. Hetzel, C., et al. (2009) Improved immunotoxins with novel functional elements, Curr. Pharm. Des., 15, pp. 2700-2711.
8. Segal E., Satchi-Fainaro, R. (2009). Design and development of polymer conjugates as anti-angiogenic agents,. Adv. Drug Deliv. Rev., 61, pp. 1159-1176.
9. Gaspar, R., Duncan, R. (2009) Polymeric carriers: Preclinical safety and the regulatory implications for design and development of polymer therapeutics, Adv. Drug Deliv. Rev., 61, pp. 1220-1231.
10. Astruc, D., Boisselier, E., Ornelas, C. (2010) Dendrimers designed for functions: from physical, photophysical, and supramolecular properties to applications in sensing, catalysis, molecular electronics, photonics, and nanomedicine, Chem. Rev., 110, pp. 1857-1959.
11. Elron-Gross, I., Glucksam,Y., Melikhov, D., Margalit, R. (2008) Cyclooxygenase inhibition by diclofenac formulated in bioadhesive carriers, Biochim. Biophys. Acta, 1778, pp. 931-936.
12. Elron-Gross, I., Glucksam, Y., Biton, I.E., Margalit, R. (2009) A novel Diclofenac-carrier for local treatment of Osteoarthritis applying live-animal MRI. J. Cont. Rel., 135, pp. 65-70.
13. Barkay, Z., Rivkin, I., Margalit, R. (2009) Three-dimensional characterization of drug-encapsulating particles using STEM detector in FEG-SEM, Micron, 40, pp. 480-485.
14. Elron-Gross, I., Glucksam, Y., Margalit, R. (2009) Liposomal dexamethasone-diclofenac combinations for local osteoarthritis treatment, Int. J. Pharma., 376, pp. 84-91.
15. Rivkin, I. et al. (2010) Paclitaxel-clusters coated with hyaluronan as selective tumor-targeted nanovectors, Biomaterials, 31, pp. 7106- 7114.
16. Torchilin, V.P. (2006) Recent approaches to intracellular delivery of drugs and DNA and organelle targeting, Annu. Rev. Biomed. Eng., 8, pp. 343-375.
17. Baum, P., Müller, D., Rüger, R., Kontermann, R.E. (2007) Single-chain Fv immunoliposomes for the targeting of fibroblast activation protein-expressing tumor stromal cells, J. Drug Target., 15, pp. 399-406.
18. Rothdiener, M., Beuttler, J., Messerschmidt, S.K., Kontermann, R.E. (2010) Antibody targeting of nanoparticles to tumor-specific receptors: immunoliposomes, Methods Mol. Biol., 624, pp. 295-308.
19. Loomis, K. et al. (2010) Specific targeting to B cells by lipid-based nanoparticles conjugated with a novel CD22-ScFv, Exp. Mol. Pathol., 88, pp. 238-249.
20. Rothdiener, M., et al. (2010) Targeted delivery of SiRNA to CD33-positive tumor cells with liposomal carrier systems, J. Cont. Rel., 144, pp. 251-258.
21. Samad, A., Sultana, Y., Aqil, M. (2007) Liposomal drug delivery systems: an update review, Curr. Drug Deliv., 4, pp. 297-305.
22. Kratz, F. (2008) Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles, J. Cont. Rel., 132, pp. 171-183.
23. Chan, O.C.M., So, K.-F., Chan, B.P. (2008) Fabrication of nano-fibrous collagen microspheres for protein delivery and efects of photochemical crosslinking on release kinetics, J. Cont. Rel., 129, pp. 135-143.
24. Gardner, E.R., Dahut, D., Figg, W.D. (2008) Quantitative determination of total and unbound paclitaxel in human plasma following Abraxane treatment, J. Chromatogr. B, 862, pp. 213-218.
25. Yongsheng, M.Y. et al. (2008) Microencapsulation of bacteriophage Felix O1 into chitosan-alginate microspheres for oral delivery, Appl. Environ. Microbiol., 74, pp. 4799-4805.
26. Matricardi, P. , Di Meo, C., Coviello, T., Alhaique, F. (2008) Recent advances and perspectives on coated alginate microspheres for modified drug delivery, Expert Opin. Drug Deliv., 5, pp. 417-425.
27. Amidi, M., Mastrobattista, E., Jiskoot, W., Hennink, W.E. (2010) Chitosan-based delivery systems for protein therapeutics and antigens, Adv. Drug Deliv. Rev., 62, pp. 59-82.
28. Peer, D. et al (2008) Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target, Science, 319, pp. 627-630.
29. de Smidt, P.C., van Berkel, T.J. (1990) LDL-mediated drug targeting, Crit. Rev. Ther. Drug Carrier Syst., 7, pp. 99-120.
30. Peer, D., Margalit, R.(2004) Loading Mitomycin C inside long circulating hyaluronan targeted nano-liposomes increases its antitumor activity in three mice tumor models, Int. J. Cancer 108, pp. 780-789.
31. Peer, D., Margalit, R. (2004). Tumor-targeted hyaluronan nano-liposomes increase the antitumor activity of liposomal doxorubicin in syngeneic and human xenograft mouse tumor models, Neoplasia, 6, pp. 343-353.
32. Nobs, L., Buchegger, F., Gurny, R., Alle'manni, E. (2004) Current methods for attaching targeting ligands to liposomes and nanoparticles, J. Pharm. Sci., 93, pp. 1980-1092.
33. Davis, M.E, Zhuo, G., Chen, Z., Shin, D.M. (2008) Nanoparticle therapeutics: an emerging treatment modality for cancer. Nature Rev. Drug Discov., 7, pp. 771-782.
34. Sega, E.I., Low, P.L. (2008) Tumor detection using folate receptor-targeted imaging agents, Cancer Metastasis Rev., 27, pp. 655-664.
35. Gabizon, A. et al. (2010) Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models, Cancer Chemother. Pharmacol., 66, pp. 43-52.
36. Xianjun, Y.X. et al. (2010) Targeted drug delivery in pancreatic cancer. BBA Rev. Cancer, 1805, pp. 97-104.
37. Garanger, E., Didier, B. Pascal, D. (2007) Tumor targeting with RGD peptide ligands-design of new molecular conjugates for imaging and therapy of cancers, Anti-Cancer Agents Med. Chem., 7, pp. 552-558.
38. Vivès, E., Schmidt, J., Pèlegrin, A. (2008) Cell-penetrating and cell-targeting peptides in drug delivery, BBA Rev. Cancer, 1786, 126-138.
39. Dekel, Y., Glucksam, Y., Margalit, R. (2010) Novel fibrillar insulin formulations for oral administration: formulation and in vivo studies in diabetic mice, J. Cont. Rel., 143, pp. 128-135.
40. Platt, V.M., Szoka, F.C. (2008). Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor, Mol. Pharm., 5, pp. 474-486.
41. Kanellakopoulou, K., Giamarellos-Bourboulis, E.J. (2000) Carrier systems for the local delivery of antibiotics in bone infections, Drugs, 59, pp. 1223-1232.
42. Zhang J.-S., Liu, F., Huang, L. (2005) Implications of pharmacokinetic behavior of lipoplex for its inflammatory toxicity, Adv. Drug Deliv. Rev., 57, pp. 689-698.
43. Lv, H. et al. (2006). Toxicity of cationic lipids and cationic polymers in gene delivery, J. Cont. Rel., 114, pp. 100-109.
44. de Ilarduyaa, C.T., Sunb, Y., Duzgunes, N. (2010) Gene delivery by lipoplexes and polyplexes, Eur. J. Pharm. Sci., 40, pp. 159-170.
45. Alving, C.R. et al. (1978) Improved therapy of experimental leishmaniasis by use of a liposome-encapsulated antimonail drug, Life Sci., 22, pp. 1021-1026.
46. Raz, A. et al. (1981) Biochemical, morphological, and ultrastructural studies on the uptake of liposomes by murine macrophages, Cancer Res., 41, pp. 487-494.
47. Isaiah, I.J. et al. (1981) The role of plasma membrane receptors and the kinetics of macrophage activation by lymphokines encapsulated in liposomes, Cancer Res., 41, pp. 495-504.
48. Kirsh, R., Bugelski, P.J., Poste, G. (1987) Drug delivery to macrophages for the therapy of cancer and infectious diseases, Ann. N.Y. Acad. Sci., 507, pp. 141-154.
49. Nardin, A. et al. (2006) Liposomal muramyl tripeptide phosphatidylethanolamine: targeting and activating macrophages for adjuvant treatment of osteosarcoma, Curr. Cancer Drug Targets, 6, pp. 123-133.
50. Bhowmick, S., Mazumdar, T., Sinha, R.. Ali, N. (2010), Comparison of liposome based antigen delivery systems for protection against Leishmania donovani, J. Control. Release, 141, pp. 199-207.
51. Gabizon, A., Shmeeda, H., Barenholtz, Y. (2003) Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies, Clin. Pharmacokinet., 42, pp. 419-436
52. Allen, T.M., Martin, F.J. (2004) Advantages of liposomal delivery systems for anthracyclines, Semin. Oncol., 31, 5-15.
53. Immordino, M.L., Dosio, F., Cattel, L. (2006) Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential, Int. J. Nanomed., 1, pp. 297-315.
54. Soloman, R., Gabizon, A.A. (2008) Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal doxorubicin. Clin. Lymphoma Myeloma, 8, pp. 21-32.
55. Schneider, G.F. et al. (2009) Multifunctional cytotoxic stealth nanoparticles. a model approach with potential for cancer therapy, Nano Lett., 9, pp. 636-642.
56. Grenader, T. et al. ((2009) Long-term response to pegylated liposomal doxorubicin in patients with metastatic soft tissue sarcomas, Anti-Cancer Drugs, 20, pp. 15-20.
57. Torchilin, V. (2008) Antibody-modified liposomes for cancer chemotherapy, Exp. Opin. Drug Deliv., 5, pp. 1003-1025.
58. Gabizon, A. et al.(2010) Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models. Cancer Chemo. Pharm., 66, pp. 43-52.
59. Petros, R.A., DeSimone, J.M. (2010) Strategies in the design of nanoparticles for therapeutic applications, Nat. Rev. Drug Discov., 9, pp. 615-627.
60. Huang Y.-H. et al (2009) Nanoparticle-delivered suicide gene therapy efectively reduces ovarian tumor burden in mice. Cancer Res. 69, pp. 6184-6191.
61. Ahmed, M. et al. (2010) Pharmacokinetics of doxorubicin after intratumoral injection using a thermosensitive hydrogel in tumor-bearing mice, J. Control. Release, 142, pp. 101-107.
62. Morishita, M., Peppas, N.A. (2006) Is the oral route possible for peptide and protein drug delivery? Drug Discov. Today, 11, pp. 905-910.
63. Singh, R., Singh, H., Lillard, J.W. (2008) Past, present, and future technologies for oral delivery of therapeutic proteins, J. Pharm. Sci., 97, pp. 2497-2523.
64. Muller, G. (2010) Oral delivery of protein drugs: driver for personalized medicine? Curr. Issues Mol. Biol., 13, pp. 13-24.
65. Arbit, E., Kidron, M. (2009) Oral insulin: the rationale for this approach and current developments, J. Diab. Sci. Technol., 3, pp. 562-567.